Track topics on Twitter Track topics that are important to you
This is an open-label pilot study to determine the safety and tolerability of infusions of autologous CD4+ CD25+ regulatory T cells with concomitant subcutaneous IL-2 injections in 4 subjects with ALS.
This Pilot Study will consist of 4 ALS subjects who will undergo 4 infusions of autologous expanded Tregs with concomitant subcutaneous injections of IL-2 (2 x 105 IU/m2) 3 times weekly for 52 weeks or at least until such time that interim analyses can confirm or negate its benefit.
During the enrollment period up to four subjects will be recruited from patients known to our clinic for screening, baseline measures and leukapheresis. The Treg cell manufacturing will be performed in a GMP laboratory. The first subject will receive infusions of their expanded Tregs (1x106 /kg) with concomitant subcutaneous IL-2 injections (2 x 105 IU/m2) 25 days (+/- 2 days) post leukapheresis. The 2nd subject will begin after the first subject has completed the first 4 weeks and has experienced no untoward effects during this period. Once subjects #1 and #2 have completed the first 4 weeks and no toxic events have occurred they will therefore be considered safely past the first milestone and subject #3 will begin infusions. After subject #3 has completed the first 4 weeks with no untoward effects, subject #4 may begin infusions with the below modified schedule:
The 4th subject will undergo infusion of autologous expanded Tregs once every four weeks (+/- 2 days) for a total of four infusions, with concomitant subcutaneous injections of IL-2 (2 x 105 IU/m2) 3 times weekly. In addition, subject #4 will begin subcutaneous IL-2 injections 4 weeks before his first autologous Treg infusion. An additional office visit will take place 2 weeks after initiating IL-2 for clinical evaluation, scoring and blood draw. Office visits will then be completed every two weeks while the subject is receiving Treg infusions for clinical evaluation, scoring, and blood draws. Then, the subject will be seen in office visits once per month for one year total for clinical evaluation, scoring, and blood draws.
In addition, subjects #1, 2 and 3 will repeat the leukapheresis (under a separate protocol) and undergo Treg infusions at the modified schedule of every 4 weeks, with concomitant subcutaneous injections of IL-2 (2 x 105 IU/m2) 3 times weekly. The subjects will be called on Day 7, and 21. Office visits will be completed on the day after infusions and every two weeks while the subjects are undergoing Treg infusions for clinical evaluation, scoring, and blood draws. The subjects will then be seen during office visits once per month for one year total from their initial baseline visit for clinical evaluation, scoring, and blood draws
Monthly interim analyses will monitor the subjects using validated ALS scales such as the ALSFRS-R and Appel Scale, which incorporates muscle strength and dysfunction, activities of daily living and pulmonary function. The analyses will also include interim medical history and physical exam, EKG when indicated, safety labs (such as CBC, chemistry, liver function, T4 and TSH) as well as more technical research labs such as T Regulatory Cell, Th1 and Th17 counts, FoxP3 RNA expression, and Treg Suppression Assays. A PT/PTT will be performed only if the subject has an abnormal coagulation result at baseline or if the subject is on anti-coagulation therapy.
ALS (Amyotrophic Lateral Sclerosis)
Autologous T-regulatory lymphocytes, Interleukin-2
Methodist Neurological Institute
Active, not recruiting
The Methodist Hospital System
Published on BioPortfolio: 2017-08-07T13:53:21-0400
The goal of this study is to investigate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells administration in the individuals with diagnosed amyotrophic l...
The study aims to evaluate primarily safety of two injections of autologous mesenchymal stem cells in Amyotrophic Lateral Sclerosis patients. Secondary outcomes of efficacy will also be ev...
The goal of this study is to investigate the safety and tolerability of allogeneic Wharton's jelly-derived mesenchymal stem cells administration in the individuals with diagnosed amyotroph...
To assess the safety of peripheral blood mononuclear cell transplantation into the subarachnoid space for the treatment of amyotrophic lateral sclerosis.
The purpose of this clinical trial is to asses the feasibility and the security of the intraspinal infusion of autologous bone marrow stem cells for the treatment of Amyotrophic Lateral Sc...
Although amyotrophic lateral sclerosis (ALS) incidence has been stable among Western countries, population-ageing effect will probably increase the proportion of very-old ALS patients. We aim to study...
After the demonstration of a corticoefferent propagation pattern in amyotrophic lateral sclerosis (ALS) by neuropathological studies, this concept has been used for in vivo staging of individual patie...
To assess the safety and efficacy of two repeated intrathecal injections of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in amyotrophic lateral sclerosis (ALS).
There are no reliable biomarkers that could evaluate the disease burden in amyotrophic lateral sclerosis (ALS).
There are some indications of increasing incidence of amyotrophic lateral sclerosis (ALS). Awareness of cognitive impairment in ALS has increased in recent years. We describe the epidemiology and clin...
A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.
Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.
A superoxide dismutase (SOD1) that requires copper and zinc ions for its activity to destroy SUPEROXIDE FREE RADICALS within the CYTOPLASM. Mutations in the SOD1 gene are associated with AMYOTROPHIC LATERAL SCLEROSIS-1.
Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...